Company intelligence / Profile preview

GACD

Irvine, California, United Statesgacd.org ↗

Ownership: Private
Development stage: Other

Overview

GATC Health has developed a proprietary AI-driven Multiomics Advanced Technology™ (MAT) platform that simulates human biochemistry at scale to rapidly create novel therapeutics, identify optimal disease targets, predict efficacy/safety/off-target effects, and accelerate drug development. The MAT platform has been validated through strategic collaborations with pharmaceutical companies such as Lisata Therapeutics. At least one internal program targeting opioid use disorder is advancing through IND-enabling studies[4][7].

Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Partnerships

Lisata Therapeutics – Strategic collaboration to apply MAT for optimizing drug development of certepetide and other assetsAdditional undisclosed pharma/biotech industry partners leveraging MAT for pipeline acceleration

Beyond the preview

Go deeper on GACD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GACD.

Explore the full profile